摘要
嵌合抗原受体T细胞(CAR-T)是一种过继细胞免疫疗法,其通过基因手段改造T细胞,从而发挥肿瘤靶向杀伤作用。CAR-T细胞疗法在治疗肿瘤,特别是血液系统恶性肿瘤方面具有显著的作用,但在实体肿瘤中作用不佳。单靶点的CAR-T在应用的过程中容易出现脱靶效应,存在复发或更加难治的风险。双靶点或多靶点CAR-T的开发有望扩大靶细胞抗原覆盖率,有效避免抗原逃逸和防止肿瘤复发,延长患者的生存时间。本文综述了目前多靶点嵌合抗原受体T细胞的研究进展,并探讨了其发展的前景。
Chimeric antigen receptor T cell(CAR-T)is a kind of adoptive cell immunotherapy,in which T cells are genetically modified to exert targeted killing effect on tumors.CAR-T cell therapy has shown remarkable antitumor efficacy for the treatment of tumors,especially for hematological malignancies,but is less effective in solid tumors.Single-target CAR-T is prone to off-target effect during application,and there is a risk of relapse or more refractory treatment.The development of double-target or multi-target CAR-T is expected to extend the antigen coverage of target cells,effectively avoids antigen escape and prevents tumor recurrence,and prolongs the survival time of patients.This article reviews the advances of multi-target chimeric antigen receptor T cell,and discusses the prospect of its development.
作者
蒋遥
温伟红
杨发
聂迪森
张武合
秦卫军
JIANG Yao;WEN Weihong;YANG Fa;NIE Disen;ZHANG Wuhe;QIN Weijun(Department of Urology,Xijing Hospital of Air Force Military Medical University,Xi’an 710054,China;Medical Research Institute of Northwestern Polytechnical University,Xi’an 710000,China;Department of Urology,Air Force 986 Hospital,Xi’an 710054,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第7期709-714,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金面上项目(82173204)
陕西创新能力支撑项目(2020PT-021)
中央高校基本科研业务费专项资金(G2021KY05102)。